Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy

Osteosarcoma is still associated with limited response to standard-of-care therapy and alarmingly elevated mortality rates, especially in low- and middle-income countries. Despite multiple efforts to repurpose β-blocker propranolol in oncology, its potential application in osteosarcoma management re...

Descripción completa

Detalles Bibliográficos
Autores principales: Solernó, Luisina M., Sobol, Natasha T., Gottardo, María F., Capobianco, Carla S., Ferrero, Maximiliano R., Vásquez, Liliana, Alonso, Daniel F., Garona, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458647/
https://www.ncbi.nlm.nih.gov/pubmed/36075937
http://dx.doi.org/10.1038/s41598-022-18324-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458647/
https://www.ncbi.nlm.nih.gov/pubmed/36075937
http://dx.doi.org/10.1038/s41598-022-18324-3

Ejemplares similares